CL2012003091A1 - Compuestos derivados de fenilalquilaminas sustituidas; metodo de tratamiento; y su uso en el tratamiento o la profilaxis de lupus eritematoso cutaneo subagudo, agudo o crónico, lupus eritematoso apolloso, hipertrofico, profundo, túmido o neonatal y en las condiciones autoinmunes asociadas. - Google Patents

Compuestos derivados de fenilalquilaminas sustituidas; metodo de tratamiento; y su uso en el tratamiento o la profilaxis de lupus eritematoso cutaneo subagudo, agudo o crónico, lupus eritematoso apolloso, hipertrofico, profundo, túmido o neonatal y en las condiciones autoinmunes asociadas.

Info

Publication number
CL2012003091A1
CL2012003091A1 CL2012003091A CL2012003091A CL2012003091A1 CL 2012003091 A1 CL2012003091 A1 CL 2012003091A1 CL 2012003091 A CL2012003091 A CL 2012003091A CL 2012003091 A CL2012003091 A CL 2012003091A CL 2012003091 A1 CL2012003091 A1 CL 2012003091A1
Authority
CL
Chile
Prior art keywords
lupus erythematosus
treatment
apollolosus
thymid
subacute
Prior art date
Application number
CL2012003091A
Other languages
English (en)
Spanish (es)
Inventor
Gergely Peter
Wallstrom Erik
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42199281&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003091(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2012003091A1 publication Critical patent/CL2012003091A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/30—Sulfides having the sulfur atom of at least one thio group bound to two carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2012003091A 2010-05-06 2012-11-06 Compuestos derivados de fenilalquilaminas sustituidas; metodo de tratamiento; y su uso en el tratamiento o la profilaxis de lupus eritematoso cutaneo subagudo, agudo o crónico, lupus eritematoso apolloso, hipertrofico, profundo, túmido o neonatal y en las condiciones autoinmunes asociadas. CL2012003091A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10162079 2010-05-06

Publications (1)

Publication Number Publication Date
CL2012003091A1 true CL2012003091A1 (es) 2013-03-22

Family

ID=42199281

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003091A CL2012003091A1 (es) 2010-05-06 2012-11-06 Compuestos derivados de fenilalquilaminas sustituidas; metodo de tratamiento; y su uso en el tratamiento o la profilaxis de lupus eritematoso cutaneo subagudo, agudo o crónico, lupus eritematoso apolloso, hipertrofico, profundo, túmido o neonatal y en las condiciones autoinmunes asociadas.

Country Status (24)

Country Link
US (1) US20130172297A1 (enExample)
EP (1) EP2566470A1 (enExample)
JP (1) JP2013530937A (enExample)
KR (1) KR20130066630A (enExample)
CN (1) CN102869353A (enExample)
AU (1) AU2011249784B2 (enExample)
BR (1) BR112012028190A2 (enExample)
CA (1) CA2795394A1 (enExample)
CL (1) CL2012003091A1 (enExample)
CR (1) CR20120566A (enExample)
CU (1) CU20120154A7 (enExample)
EA (1) EA201201514A1 (enExample)
EC (1) ECSP12012312A (enExample)
IL (1) IL222690A0 (enExample)
MA (1) MA34285B1 (enExample)
MX (1) MX2012012926A (enExample)
NZ (1) NZ603999A (enExample)
PE (1) PE20130612A1 (enExample)
PH (1) PH12012502418A1 (enExample)
SG (1) SG185746A1 (enExample)
TN (1) TN2012000509A1 (enExample)
TW (1) TW201201814A (enExample)
WO (1) WO2011138393A1 (enExample)
ZA (1) ZA201207710B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI519539B (zh) 2010-12-21 2016-02-01 Kyorin Seiyaku Kk Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof
US9289494B2 (en) 2013-11-20 2016-03-22 RestorTears, LLC Method of treating ocular disorders with compounds found in Harderian gland secretions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029184A1 (en) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
AU2002332289B2 (en) * 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
US7482491B2 (en) 2002-09-19 2009-01-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
WO2004074297A1 (ja) * 2003-02-18 2004-09-02 Kyorin Pharmaceutical Co., Ltd. アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤
ES2351393T3 (es) * 2003-05-26 2011-02-03 Takeda Pharmaceutical Company Limited Sulfopirroles.
MXPA06002349A (es) 2003-08-28 2006-05-22 Novartis Ag Derivados de aminopropanol.
CN1918148B (zh) * 2004-02-11 2012-09-05 巴斯利尔药物股份公司 取代的苯并咪唑和它们诱导细胞凋亡的用途
JPWO2006041015A1 (ja) * 2004-10-12 2008-05-15 杏林製薬株式会社 アミノアルコール誘導体とその付加塩及び免疫抑制剤
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds
CA2820510A1 (en) * 2005-09-09 2007-03-15 Novartis Ag Treatment of autoimmune diseases

Also Published As

Publication number Publication date
EA201201514A1 (ru) 2013-05-30
ECSP12012312A (es) 2012-12-28
AU2011249784A1 (en) 2012-12-20
TN2012000509A1 (en) 2014-04-01
CA2795394A1 (en) 2011-11-10
KR20130066630A (ko) 2013-06-20
TW201201814A (en) 2012-01-16
AU2011249784B2 (en) 2014-03-06
WO2011138393A1 (en) 2011-11-10
CN102869353A (zh) 2013-01-09
PH12012502418A1 (en) 2018-03-21
SG185746A1 (en) 2013-01-30
ZA201207710B (en) 2013-06-26
NZ603999A (en) 2014-06-27
PE20130612A1 (es) 2013-06-06
CU20120154A7 (es) 2013-03-27
MA34285B1 (fr) 2013-06-01
IL222690A0 (en) 2012-12-31
US20130172297A1 (en) 2013-07-04
CR20120566A (es) 2013-01-09
BR112012028190A2 (pt) 2016-08-02
MX2012012926A (es) 2012-12-17
JP2013530937A (ja) 2013-08-01
EP2566470A1 (en) 2013-03-13

Similar Documents

Publication Publication Date Title
EA201692316A1 (ru) Производные холана для применения при лечении и/или профилактике fxr и tgr5/gpbar1-опосредованных заболеваний
CL2016002310A1 (es) Nuevos compuestos bicíclicos.
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
MX384420B (es) Cultivo, producción, procesamiento y uso de cannabis de especialidad.
CR20140576A (es) Sintesis de compuestos heterociclicos
GT201200289A (es) 3-sustituido-5-fluoro-4-imino-3,4-dihidropirimidina-2-(1h)-onas como fungicidas
EP3673877C0 (en) SYSTEMS FOR THE TREATMENT OF POLYCYSTIC OVARIAN SYNDROME
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
PL3495473T3 (pl) Sposób rozszczepienia hydrolitycznego zearalenonu i/lub pochodnych zearalenonu przy pomocy polipeptydu, jak i jego zastosowanie
MX381488B (es) Indoles para su uso en la infección por el virus de la gripe.
IT1400509B1 (it) Apparecchiatura e metodo per il trattamento di disidratazione spinta di fanghi.
LT3113858T (lt) Konjugatų il-15/il-15r alfa pagrindu gryninimo būdas
EA201490559A1 (ru) Композиция для лечения свища
EA201792096A3 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
DK3019452T3 (da) Fremgangsmåde for og installation af biologisk denitrifikation af spildevand
MX386150B (es) Tasimelteon para tratar el síndrome de smith-magenis.
CR20150417A (es) Compuestos de azetidiniloxifenilpirrolidina
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
UA107346C2 (en) Use of nifuratel to treat infections caused by atopobium species
PL3393984T3 (pl) Instalacja i sposób biologicznego przetwarzania odpadów i ścieków organicznych
ES2663096T3 (es) Métodos para el tratamiento del síndrome nefrótico y de afecciones relacionadas
CL2012003091A1 (es) Compuestos derivados de fenilalquilaminas sustituidas; metodo de tratamiento; y su uso en el tratamiento o la profilaxis de lupus eritematoso cutaneo subagudo, agudo o crónico, lupus eritematoso apolloso, hipertrofico, profundo, túmido o neonatal y en las condiciones autoinmunes asociadas.
CL2012001758A1 (es) Uso de compuestos derivados de 8-hidroxiquinolin-7-carboxamida y sus sales, para el tratamiento y/o prevencion de infecciones fungicas.
UY33542A (es) Uso de teriflunomida para tratar la esclerosis múltiple